



## Wave Life Sciences to Present at Stifel 2022 CNS Days

March 21, 2022

CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) – Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate virtually in an analyst-led fireside chat at the Stifel 2022 CNS Days event on Monday, March 28, 2022, at 9:15 a.m. EDT.

A live webcast of the presentation will be available on the Investor Relations page of the Wave Life Sciences corporate website at <http://ir.wavelifesciences.com>. A replay of the presentation will be archived and available at that site for a limited time following the event.

### About Wave Life Sciences

Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company's proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit [www.wavelifesciences.com](http://www.wavelifesciences.com) and follow Wave on Twitter [@WaveLifeSci](https://twitter.com/WaveLifeSci).

### Investor Contact:

Kate Rausch  
617-949-4827  
[krausch@wavelifesci.com](mailto:krausch@wavelifesci.com)

### Media Contact:

Alicia Suter  
617-949-4817  
[asuter@wavelifesci.com](mailto:asuter@wavelifesci.com)



Source: Wave Life Sciences USA, Inc.